TY - JOUR
T1 - A Standardized and Regionalized Network of Care for Cardiogenic Shock
AU - Tehrani, Behnam N.
AU - Sherwood, Matthew W.
AU - Rosner, Carolyn
AU - Truesdell, Alexander G.
AU - Ben Lee, Seiyon
AU - Damluji, Abdulla A.
AU - Desai, Mehul
AU - Desai, Shashank
AU - Epps, Kelly C.
AU - Flanagan, Michael C.
AU - Howard, Edward
AU - Ibrahim, Nasrien
AU - Kennedy, Jamie
AU - Moukhachen, Hala
AU - Psotka, Mitchell
AU - Raja, Anika
AU - Saeed, Ibrahim
AU - Shah, Palak
AU - Singh, Ramesh
AU - Sinha, Shashank S.
AU - Tang, Daniel
AU - Welch, Timothy
AU - Young, Karl
AU - deFilippi, Christopher R.
AU - Speir, Alan
AU - O'Connor, Christopher M.
AU - Batchelor, Wayne B.
N1 - Funding Information:
Dr Tehrani has served on the advisory board for Abbott; has received research grants from Boston Scientific and Inari Medical; and has served as a consultant for Boston Scientific. Dr Truesdell has served as a consultant for Abiomed. Dr Ibrahim has received honoraria from Medtronic. Dr Shah is supported by a National Institutes of Health K23 Career Development Award 1K23HL143179; has served as a consultant for Merck, Novartis, and Procyrion; and his institution has received grant support from Abbott, Roche, Merck and Bayer for unrelated research. Dr Batchelor has served as consultant for Boston Scientific, Abbott, Medtronic, and V-Wave. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
The authors would like to thank the Dudley Family for their continued contributions and support of the Inova Dudley Family Center for Cardiovascular Innovation. The authors would also like to thank the Inova Heart and Vascular Institute cardiovascular disease fellows—Drs Emmanuel Ekanem, Hooman Bakhshi, Leonard Genovese, Raghav Gattani, Araba Ofosu-Somuah, and Xiaoxiao Qian—for their clinical and research contributions to the Inova Cardiogenic Shock Program. Graphic design support was provided by Ms Devon Stuart under the guidance and direction of the authors.
Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/10
Y1 - 2022/10
N2 - Background: The benefits of standardized care for cardiogenic shock (CS) across regional care networks are poorly understood. Objectives: The authors compared the management and outcomes of CS patients initially presenting to hub versus spoke hospitals within a regional care network. Methods: The authors stratified consecutive patients enrolled in their CS registry (January 2017 to December 2019) by presentation to a spoke versus the hub hospital. The primary endpoint was 30-day mortality. Secondary endpoints included bleeding, stroke, or major adverse cardiovascular and cerebrovascular events. Results: Of 520 CS patients, 286 (55%) initially presented to 34 spoke hospitals. No difference in mean age (62 years vs 61 years; P = 0.38), sex (25% vs 32% women; P = 0.10), and race (54% vs 52% white; P = 0.82) between spoke and hub patients was noted. Spoke patients more often presented with acute myocardial infarction (50% vs 32%; P < 0.01), received vasopressors (74% vs 66%; P = 0.04), and intra-aortic balloon pumps (88% vs 37%; P < 0.01). Hub patients were more often supported with percutaneous ventricular assist devices (44% vs 11%; P < 0.01) and veno-arterial extracorporeal membrane oxygenation (13% vs 0%; P < 0.01). Initial presentation to a spoke was not associated with increased risk-adjusted 30-day mortality (adjusted OR: 0.87 [95% CI: 0.49-1.55]; P = 0.64), bleeding (adjusted OR: 0.89 [95% CI: 0.49-1.62]; P = 0.70), stroke (adjusted OR: 0.74 [95% CI: 0.31-1.75]; P = 0.49), or major adverse cardiovascular and cerebrovascular events (adjusted OR 0.83 [95% CI: 0.50-1.35]; P = 0.44). Conclusions: Spoke and hub patients experienced similar short-term outcomes within a regionalized CS network. The optimal strategy to promote standardized care and improved outcomes across regional CS networks merits further investigation.
AB - Background: The benefits of standardized care for cardiogenic shock (CS) across regional care networks are poorly understood. Objectives: The authors compared the management and outcomes of CS patients initially presenting to hub versus spoke hospitals within a regional care network. Methods: The authors stratified consecutive patients enrolled in their CS registry (January 2017 to December 2019) by presentation to a spoke versus the hub hospital. The primary endpoint was 30-day mortality. Secondary endpoints included bleeding, stroke, or major adverse cardiovascular and cerebrovascular events. Results: Of 520 CS patients, 286 (55%) initially presented to 34 spoke hospitals. No difference in mean age (62 years vs 61 years; P = 0.38), sex (25% vs 32% women; P = 0.10), and race (54% vs 52% white; P = 0.82) between spoke and hub patients was noted. Spoke patients more often presented with acute myocardial infarction (50% vs 32%; P < 0.01), received vasopressors (74% vs 66%; P = 0.04), and intra-aortic balloon pumps (88% vs 37%; P < 0.01). Hub patients were more often supported with percutaneous ventricular assist devices (44% vs 11%; P < 0.01) and veno-arterial extracorporeal membrane oxygenation (13% vs 0%; P < 0.01). Initial presentation to a spoke was not associated with increased risk-adjusted 30-day mortality (adjusted OR: 0.87 [95% CI: 0.49-1.55]; P = 0.64), bleeding (adjusted OR: 0.89 [95% CI: 0.49-1.62]; P = 0.70), stroke (adjusted OR: 0.74 [95% CI: 0.31-1.75]; P = 0.49), or major adverse cardiovascular and cerebrovascular events (adjusted OR 0.83 [95% CI: 0.50-1.35]; P = 0.44). Conclusions: Spoke and hub patients experienced similar short-term outcomes within a regionalized CS network. The optimal strategy to promote standardized care and improved outcomes across regional CS networks merits further investigation.
KW - cardiogenic shock
KW - hub and spoke networks
KW - systems of care
UR - http://www.scopus.com/inward/record.url?scp=85138071673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138071673&partnerID=8YFLogxK
U2 - 10.1016/j.jchf.2022.04.004
DO - 10.1016/j.jchf.2022.04.004
M3 - Article
C2 - 36175063
AN - SCOPUS:85138071673
SN - 2213-1779
VL - 10
SP - 768
EP - 781
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 10
ER -